Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy.

MLA

Synnestvedt, Marit, et al. “Combined Analysis of Vascular Invasion, Grade, HER2 and Ki67 Expression Identifies Early Breast Cancer Patients with Questionable Benefit of Systemic Adjuvant Therapy.” Acta Oncologica. Supplement, vol. 52, no. 1, Jan. 2013, pp. 91–101. EBSCOhost, https://doi.org/10.3109/0284186X.2012.713508.

APA

Synnestvedt, M., Borgen, E., Russnes, H. G., Kumar, N., Schlichting, E., Giercksky, K.-E., Kåresen, R., Nesland, J. M., & Naume, Bj. (2013). Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy. Acta Oncologica. Supplement, 52(1), 91–101. https://doi.org/10.3109/0284186X.2012.713508

Chicago

Synnestvedt, Marit, Elin Borgen, Hege G. Russnes, Neenat. Kumar, Ellen Schlichting, Karl-Erik Giercksky, Rolf Kåresen, Jahn M. Nesland, and BjøRN Naume. 2013. “Combined Analysis of Vascular Invasion, Grade, HER2 and Ki67 Expression Identifies Early Breast Cancer Patients with Questionable Benefit of Systemic Adjuvant Therapy.” Acta Oncologica. Supplement 52 (1): 91–101. doi:10.3109/0284186X.2012.713508.